Holen Sie sich die Stockscreener-App
8.1727
0.73%
-0.0773
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences - investingnews.com
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach - TipRanks
Why Did Eupraxia Pharmaceuticals (TSX:EPRX) Surge 12.36% on 4 September 2026? - kalkine.ca
Pharma Eupraxia (Nasdaq: EPRX) moves to Nasdaq's top tier - Stock Titan
No shareholder action is needed as Eupraxia shares move to Nasdaq’s highest tier. - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
EPRX Stock Jumps As Traders Eye Volatile Breakout - timothysykes.com
EPRX Jumps As Traders Focus On Cash Runway And Momentum - StocksToTrade
Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ: EPRX) Stock Price, News & Analysis - Kalkine
Eupraxia Pharmaceuticals (TSX:EPRX) Gains Momentum as Clinical Progress Supports a More Constructive Investor Outlook - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Surges 9.56% Today as RESOLVE Trial Momentum and Major Q4 Catalyst Fuel Investor Optimism - kalkine.ca
Eupraxia Pharmaceuticals Stock Slides 3.34%: Can Clinical Momentum Offset Renewed Downside Pressure? - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Slides 3.34% as Clinical-Stage Risks and Biotech Volatility Pressure Sentiment - kalkine.ca
Eupraxia Pharmaceuticals Stock Falls 8.75% as Clinical-Stage Volatility Tests Investor Confidence Despite Pipeline Potential - kalkine.ca
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Faces Downside Pressure as Biotech Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
Could Eupraxia Pharmaceuticals (TSX:EPRX) Reach Its Next Milestone? - Kalkine Media
EUPRAXIA PHARMACEUTICALS INC. SEC Filing (Aug 25, 2026) - Stock Titan
Eupraxia Pharmaceuticals Inc. (TSX:EPRX) Gains Investor Momentum as Clinical Progress and Pipeline Advancement Strengthen Biotechnology Outlook - kalkine.ca
Could Eupraxia Pharmaceuticals (TSX:EPRX) Gain Fresh Market Attention? - Kalkine Media
Eupraxia (EPRX) Watch: Finishes 0.44% Lower at $6.73 in the Latest Reading; Technical View: $6.39 and $7.07 Define the Nearby Reference Levels under the Current SnapshotPut Call Ratio - vinanet.vn
Eupraxia Pharmaceuticals Independent Director Acquires 1.4% More Stock - simplywall.st
Eupraxia Pharmaceuticals Stock Falls 4.12% as Investors Weigh Clinical Progress Against Biotech Development and Financing Risk - kalkine.ca
Eupraxia Slides as Biotech Traders Take Risk Off the Table — What Could Trigger the Next Move? - kalkine.ca
Eupraxia Pharmaceuticals Faces Fresh Downside Pressure as Clinical Execution Risk Clouds the EoE Story - kalkine.ca
Eupraxia (EPRX) Quarter in Focus: EPS Does Not Reach the Reported Estimate for This Review - vinanet.vn
Eupraxia Pharmaceuticals Market Sentiment - Benzinga France
What's Going On With Eupraxia Pharmaceuticals Inc Stock Wednesday? - Wealth Awesome
Eupraxia (Nasdaq: EPRX) lines up $300M in securities offerings - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Higher to $6.72 as Biotech Sector Holds SteadyEqual Weight ETF - vinanet.vn
Eupraxia Pharmaceuticals announces results from RESOLVE study analysis - TipRanks
Eupraxia Pharmaceuticals (EPRX) Holds Gains as Shares Trade Near $6.72MFI Overbought - vinanet.vn
Eupraxia Pharmaceuticals (EPRX) Advances 0.75% as Price Approaches Key ResistancePost-Earnings Moves - vinanet.vn
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia Pharmaceuticals (EPRX) holders report around 4–5% stakes in 13G/A - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Eupraxia Pharmaceuticals Inc EPRX Earnings Beat Estimates by 0.0% - Wealth Awesome
Eupraxia reports symptom improvements in EoE trial analysis - Investing.com
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia in Eosinophilic Esophagitis Patients - Investing News Network
Eupraxia Posts Strong Long-Term Symptom Gains in Phase 1b/2a EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients - thecanadianpressnews.ca
Eupraxia reports symptom improvements in EoE trial analysis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals (EPRX) shows durable EoE symptom relief in RESOLVE trial - Stock Titan
Eupraxia Pharmaceuticals Inc (TSX:EPRX) Shares Decline as Clinical Development Risks and Biotechnology Market Volatility Pressure Sentiment - kalkine.ca
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eupraxia Q2 EPS beats estimate despite wider net loss - scanx.trade
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results - MarketBeat
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects - TipRanks
Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M - Stock Titan
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - GlobeNewswire
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - finance.yahoo.com
Will Eupraxia Pharmaceuticals Inc (EPRX) Beat Earnings Estimates in Its Next Report? - Wealth Awesome
Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eupraxia Pharmaceuticals (NASDAQ: EPRX) sets up US$300M mixed securities shelf - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Edges Lower to $6.48, Holding Between Support and ResistancePut Wall - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) to Post Earnings on Tuesday - MarketBeat
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):